Gates Package — page 43

This is coming together very nicely. I'd like to suggest a follow-up call to discuss this in more detail and have cc'd our colleagues at CBR who have been leading the regulatory and clinical planning effort for ZMapp. Assuming everyone agrees a call would be worthwhile, can I trouble CBR to arrange it? Best, Larry From: Trina Racine BE ¢ 2h 2c-2s0c.g¢.ca<maiito:trina racine@phac-aspc.gc.ca><mailtortrina.racine@ phacaspc.gc.ca>> Date: Wednesday, July 30, 2014 at 8:43 AM To: deborah scott (EEE © sbcclobal net<mailto ENO sbcelobal net><mailto EEO sbcglobal.net>> Ce: Frederick G *HS Hayden Ee bscmail.mce.virginia.edu<mailto {@hscmail.mcc.virginia.edu><mailto {fe hscmail.mcc.virginia.edu>>, Gary Kobinger <gary. kobinger @phac-aspc.gc.ca<mailto:gary.kobinger @phac-aspc.gc.ca><mailto:gary.kobinger@phacaspc.gc.ca>>, Gene Olinger {ENO nih.gov<mailto JH nih.gov><mailto JO nih.gov>>, Peter Jahrling <M© niaid.nih.gov<mailto fo niaid.nih.gov><mailto {MO niaid.nih.gov>>, Mike Hensley HO icloud.com<mailto fMH@ icloud.com><mailto f@icloud.com>>, Larry Zeitlin mappbio.com<mailto mappbio.com><mailto {© mappbio.com>>, Lisa Hensley gov<mailto: nih.gov><mailto {ENO nih.gov>> Subject: Re: Combining the existing Phase 1 with a Therapeutic Portion Hello all, I too have made a number of comments and edits. Please let me know if you would like to discuss. Trina From: deborah scott (EE sbcglobal.net<mailto sbeglobal.net><mailto: sbeglobal.net>> To: Mike Hensley SS endo ce ets nat icloud.com>>, Larry Zeitlin E62 pbio.com<mailto fF mappbio.com><mailto: mappbio.com>> Ce: Frederick G *HS Hayden hscmail.mcc.virginia.edu<mailto {jg@hscmail.mcc.virginia.edu><mailto {fo hscmail.mcc.virginia.edu>>, "Peter \(NIH/NIAID\) \[E\] Jahrling" niaid.nih.gov<mailto: niaid.nih.gov><mailto: niaid.nih.gov>>, "Lisa \(NIH/NIAID\) \[E\] Hensley" nih.gov<mailto nih.gov><mailto: nih.gov>>, nih.gov<mailto: nih.gov><mailto: nih.gov> \[C\] Olinger" nih.gov<mailto: nih.gov><mailto: nih.gov>>, "Gary \(Public Health Agency of Canada\) Kobinger" <gary.kobinger@phac-aspc.gc.ca<mailto:gary.kobinger@phacaspc.gc.ca><mailto iP phac-aspc.gc.ca>>, Trina Racine phacaspc.gc.ca<mailto: © phac-aspe.gc.ca><mailt phac-aspc.ge.ca>> Date: 2014-07-30 12:39 AM Subject: Re: Combining the existing Phase 1 with a Therapeutic Portion